A quantitative comparison of cytogenetic effects of anti-tumor agents

Area of Science:

• Cytogenetics and Molecular Toxicology
• Cancer Research and Drug Development

Background:

• Anti-tumor agents are crucial in cancer therapy.
• Understanding their genotoxic potential, including chromosome damage, is vital for assessing safety and efficacy.
• Standardized comparisons of different agents' potencies are needed.

Purpose of the Study:

• To compare the relative potency of various anti-tumor agents in inducing chromosome abnormalities.
• To assess the relationship between structural and numerical chromosome aberrations and sister chromatid exchanges (SCEs).
• To establish a standardized method for evaluating genotoxicity at equitoxic doses.

Main Methods:

• Cultured diploid human fibroblasts were treated with equitoxic doses of X-rays, daunorubicin, nitrogen mustard, adriamycin, and actinomycin D.
• Equitoxicity was determined by colony-forming ability, aiming for approximately 20% survival.
• Chromosome aberrations (structural and numerical) and SCEs were analyzed.

Main Results:

• Relative potency for inducing structural aberrations at ~20% survival: X-rays (1.0) > daunorubicin (0.85) > nitrogen mustard (0.26) > adriamycin (0.22) > actinomycin D (0).
• Sister chromatid exchange (SCE) induction was quantitatively unrelated to chromosome aberration induction.
• No numerical chromosome changes were observed across the tested agents.

Conclusions:

• X-rays, daunorubicin, nitrogen mustard, and adriamycin exhibit varying potencies in inducing structural chromosome damage.
• Actinomycin D showed no significant induction of structural aberrations under the tested conditions.
• Accurate assessment of chromosome aberrations requires multiple sampling times in asynchronous cell populations.